Overview: Alpha-Fetoprotein (AFP) Marker Rapid TestIntroduction: The Alpha-Fetoprotein (AFP) Marker Rapid Test is a diagnostic tool designed to detect AFP levels in serum or plasma samples, facilitating the screening of liver cancer or fetal abnormalities. AFP, a protein produced during fetal development, is elevated in hepatocellular carcinoma, germ cell tumors, or conditions like neural tube defects, presenting with abnormal liver function, jaundice, or developmental issues if untreated, particularly in at-risk populations or pregnant women. Per the 2023 American Cancer Society guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in primary care or prenatal settings. This rapid diagnostic falls under clinical pathology and targets individuals with liver disease symptoms or pregnancy-related risks, addressing the challenge of early detection to guide further imaging or amniocentesis and improve outcomes. With morbidity rates elevated due to late diagnosis, the test supports public health efforts by enabling early identification, facilitating specialist referrals, and reducing cancer mortality or birth defects. Its dual-sample capability enhances its utility.Other Names: AFP Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Abbott, this test advanced AFP detection, providing a rapid alternative to enzyme immunoassays.Purpose: The test screens for AFP to guide liver cancer or fetal abnormality diagnosis, assess disease or developmental risk, and inform treatment and prevention strategies.Test Parameters: Presence of Alpha-Fetoprotein, detected with reasonable specificity to indicate elevated levels, typically detectable in serum or plasma during active disease or fetal development anomalies.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, abdominal pain, or pregnancy status.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve protein integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade proteins, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on jaundice, weight loss, liver disease history, or pregnancy complications, as well as any prior cancer screenings or family history.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including cancer or birth defects, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent liver injury can affect results. Correlation with ultrasound, MRI, or amniocentesis is recommended to confirm findings.Clinical Significance: A positive result indicates elevated AFP, necessitating further investigation like biopsy or fetal ultrasound. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the detection window.Specialist Consultation: Oncologists, hepatologists, or obstetricians should be consulted for case management, treatment planning, and coordination with prenatal or cancer care programs.Additional Supporting Tests: Liver biopsy, ultrasound, or AFP follow-up assays for confirmation.Test Limitations: The test may produce false positives due to benign liver conditions or false negatives in early cancer, requiring a comprehensive diagnostic approach that includes imaging and clinical correlation.References: ACS Guidelines 2023, Journal of Clinical Oncology 2024, Obstetrics and Gynecology 2025.